StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PRISMMEDI.BO$29.20+0.69%
Fair $29.20+0.0%

PRISMMEDI.BO

Prism Medico and Pharmacy Limited

Consumer Defensive / Farm ProductsBSE

$29.20

+0.20 (+0.69%)

Fairly Valued+0.0%Fair Value $29.20Fund rank 23/100 · Data gapFallback financials|
SA 21/D
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 15%

FCF escenarios

weak_data · normalized FCF $-50000.00 · quality 31.7/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

21/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -0.3%, below the 5% threshold
Thesis & Journal · PRISMMEDI.BOLocal privado en este navegador · Prism Medico and Pharmacy Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$177M

P/E

34.8x

↑

EV/EBITDA

N/A

•

ROE

-0.3%

↓

Gross Margin

29.0%

↑

Debt/Equity

N/A

•
52-Week Range$29
$12$34

TradingView lightweight chart

PRISMMEDI.BO price, volumen y niveles de valoración

Último $29.20Periodo +873.3%
Fair value: $29.20

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-57.9%

FCF CAGR

—

FCF margin

-2.6%

FCF / Net income

0.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $6.3M · net income $-487000.0 · FCF $-165000.0

2022-FY → 2025-FY

Gross margin

29.0%+31.2% pts

Operating margin

-12.8%-6.9% pts

Net margin

-7.7%-3.3% pts

FCF margin

-2.6%+25.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$6.3M$6.3M$29.3M$12.7M$84.4M
Net Income$-487000.00$-487000.00$-214000.00$-763000.00$-3.7M
EBITDA$-765000.00$-765000.00$-1.4M$-970000.00$-4.9M
EPS-0.08-0.08-0.05-0.13-0.61
Gross Margin29.0%29.0%12.5%10.2%-2.2%
Operating Margin-12.8%-12.8%-4.9%-8.2%-5.9%
Net Margin-7.7%-7.7%-0.7%-6.0%-4.4%
Balance Sheet
Current Ratio77.3877.38———
Cash Flow
Free Cash Flow$-165000.00$-165000.00$-50000.00$29.5M$-23.8M
Returns
ROE-0.3%-0.3%-0.1%-0.5%-2.9%
Valuation
P/E34.7634.76———
P/B1.171.171.041.160.39
Growth & Yield
Revenue Growth-78.4%-78.4%130.2%-85.0%—
EPS Growth-60.6%-60.6%61.5%78.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +74.6%

Total return

+74.6%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.05 → -0.08

Residual

+74.6%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+74.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.